非小细胞肺癌的新辅助治疗。
Neoadjuvant Therapy in Non-Small Cell Lung Cancer.
发表日期：2023 Jul 31
作者：
Christopher Grant, Garo Hagopian, Misako Nagasaka
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
摘要：
非小细胞肺癌（NSCLC）I-III期以往主要是通过手术和化疗进行治疗。随着Checkmate-816的问世，新辅助奈伐肌单抗和化疗已经获得FDA批准用于可切除的NSCLC的治疗。目前有几项正在进行的试验评估其他新辅助化疗和免疫治疗的组合以及针对驱动基因突变的靶向治疗。在这里，我们回顾以前的临床试验，并讨论目前正在进行的试验的潜在优势和挑战。版权所有 © 2023. Elsevier B.V.发表。
Non-small cell lung cancer (NSCLC) stages I-III were previously predominantly treated with surgery and chemotherapy. With the advent of Checkmate-816, neoadjuvant nivolumab and chemotherapy was FDA approved for the treatment of resectable NSCLC. There are several ongoing trials evaluating other neoadjuvant combinations of chemotherapy and immunotherapy as well as targeted therapies towards driver mutations. Here, we review previous clinical trials and discuss current ongoing trials' potential benefits and challenges.Copyright © 2023. Published by Elsevier B.V.